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Abstract HIV gene expression is crucially dependent on
binding of the viral Tat protein to the transactivation RNA
response element. A number of synthetic Tat-transactivation
responsive element interaction inhibitors of peptide/peptoid
nature were described as potential antiviral drug prototypes.
We present a new class of peptidomimetic inhibitors, conjugates
of L-arginine with aminoglycosides. Using a gel-shift assay and
affinity chromatography on an L-arginine column we found that
these compounds bind specifically to the transactivation respon-
sive element RNA in vitro with Kd values in the range of 20^400
nM, which is comparable to the Kd of native Tat bound to the
transactivation responsive element (10^12 nM). Confocal mi-
croscopy studies demonstrated that fluorescein-labelled conju-
gate penetrates into live cells. High affinity to the transactivation
responsive element, low toxicity, and relative simplicity of
synthesis make these compounds attractive candidates for
antiviral drug design.
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1. Introduction
Human immunode¢ciency virus (HIV) gene expression de-
pends on the interaction of the viral regulatory protein, Tat,
with the transactivation responsive element (TAR), a stem-
loop RNA structure found at the 5P end of all HIV-1 tran-
scripts [1]. TAR is a positive enhancer that stimulates the
synthesis of productive transcripts and is unique in terms of
eukaryotic transcription control because it is only functional
as an RNA element. Activation by Tat is entirely dependent
on the presence of the TAR RNA sequence and it is known
that Tat activates expression by speci¢cally binding to TAR,
which increases viral mRNA production several hundred-fold
by stimulating the elongation capacity of RNA polymerase II
[2]. The Tat interaction with TAR is mediated by a nine
amino acid region RKKRRQRRR (residues 49^57) of the
protein [3,4]. Both the Tat protein and the speci¢c binding
peptide form tight complexes with the TAR RNA in vitro.
Studies with peptides suggest that a single properly positioned
arginine in a strand of lysines provides the only sequence
speci¢c contact with the three nucleotide bulge on the TAR
RNA [4^7] by forming a network of hydrogen bonds, called
by Frankel et al. [8] an ‘arginine fork’. In particular, a syn-
thetic peptide R52 (YKKKRKKKKKA), containing only one
arginine residue at position 52, binds to TAR with the same
a⁄nity as wild-type Tat 49^57 [4], which contains ¢ve arginine
residues.
NMR structural studies of the Tat binding sites of HIV and
bovine immuno de¢ciency virus (BIV) TAR demonstrate that
the conformational changes in the arginine binding site can be
induced by a number of ligands carrying a guanidinium group
[9], such as a peptide that mimics the basic region of the Tat
protein [10^12], a single arginine [13,14] or L-argininamide
[15]. NMR structures show that ligands are bound in the
major groove of the RNA [9^15]. The RNA bulge structure
allows ligands to access the major groove of TAR [10^12,16],
which induces folding in the bulge and formation of unusual
base-triples [11^15]. Based on NMR studies, the HIV Tat
peptide/TAR complex can be modeled with the basic K-helix
lying in the major groove of the RNA, such, that important
interactions of a putative speci¢city-endowing arginine are
maintained and a slight widening of the major groove is en-
tailed [17,18]. In contrast, the 17-mer BIV Tat recognition
domain folds into a L-hairpin and penetrates in an edge-on
orientation deep into a widened major groove of the 28-mer
of the BIV TAR RNA [11].
Since the structural basis of the HIV Tat-TAR interaction
was postulated [9,10,15,16], attempts to produce antiviral pep-
tide or peptidomimetic substances that inhibit Tat binding to
the TAR element were undertaken by a number of researchers
[19^21]. A synthetic peptide/peptoid compound, which e¡ec-
tively inhibits Tat binding to the TAR RNA by competing for
the Tat-binding site, was found using a combinatory approach
by screening an oligomer peptide/peptoid library of 3.2 mil-
lion entities. This compound, CGP64222, selected by the cri-
terion of in vitro inhibition of the Tat-TAR interaction, dis-
played an e⁄cient suppression of HIV replication in a cell
culture [21].
Among natural RNA-binding molecules, aminoglycoside
antibiotics have interesting properties that make them similar
to peptide RNA-binders. They are known to bind e⁄ciently
to RNA structures, such as 16S RNA or introns type I [22].
Neomycin B, tobramycin and lividomycin A inhibit the HIV
Rev-RRE interaction in vitro at concentrations of 1^10 WM,
whereas kanamycin, gentamicin, streptomycin etc. do not dis-
play any inhibition at 10^100 WM. None of the aminoglyco-
side antibiotics inhibits the Tat-TAR interaction at concen-
trations below 100 WM [23]. Recently, it was shown that
neomycin B inhibits the Tat-TAR interaction non-competi-
tively in vitro in the range of 100 WM^1 mM. This phenom-
enon was attributed to the antibiotic association with the
TAR RNA in the lower stem [24].
The above allows us to propose that an anti-HIV com-
pound, which would suppress viral replication by inhibiting
transactivation by Tat, may be prepared by combining a car-
bohydrate skeleton similar to aminoglycoside antibiotics with
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side chains of variable length bearing a guanidine moiety or a
chemical group with a similar geometry or/and charge proper-
ties, resembling peptide side chains. Here we describe the dis-
covery and preliminary studies of a new class of peptidomi-
metic TAR RNA binders: conjugates of arginine with
aminoglycoside antibiotics. These relatively low molecular
weight compounds are able to reproduce the binding behavior
of the Tat protein and are promising candidates for antiviral
drug design.
2. Materials and methods
2.1. Compounds
The synthesis and puri¢cation of the monosaccharide derivatives
(Fig. 1) and aminoglycoside-arginine conjugates (Fig. 2) and their
structures, con¢rmed by 1H, 13C NMR, 2D NMR and FAB MS,
have been recently described [25].
2.2. TAR RNA and Tat peptide preparation
A 31 nucleotide TAR RNA fragment (5P-GGC CAG AUC UGA
GCC UGG GAG CUC UCU GGC C-3P) containing the sequence
18^44 of the HIV-1 LTR [10] was transcribed in vitro by T7 RNA
polymerase (Promega) from a synthetic single strand DNA template
containing the 17 nucleotide double-stranded T7 promoter (both
DNA oligonucleotides were prepared by the Weizmann Institute
Chemical Services) [26]. The RNA was transcriptionally labelled
with [K-32P]UTP, puri¢ed on a 12% polyacrylamide/7 M urea gel
(19:1 acrylamide:bis-acrylamide) and was eluted from the gel by ex-
traction bu¡er, containing 0.5 M ammonium acetate, 10 mM magne-
sium acetate, 1 mM EDTA and 0.1% SDS. The sample was phenol-
extracted and the RNA was precipitated from 70% ethanol. Puri¢ed
RNA was dissolved in diethyl pyrocarbonate-treated water, its con-
centration was determined by UV absorption at 260 nm and the
speci¢c radioactivity was determined by scintillation counting on a
LS 1701 Bruker counter.
The model Tat peptide (Tat R52: YKKKRKKKKKA) was pre-
pared by the Weizmann Institute Chemical Services and was puri¢ed
by reverse phase HPLC (C-18) [26].
2.3. Gel-shift assay
The binding reaction mixtures (20 Wl) contained 32P-labelled TAR
(18^44) RNA oligonucleotide and the Tat R52 peptide in a binding
bu¡er (10 mM Tris-HCl pH 7.5, 70 mM NaCl, 0.2 mM EDTA, 5%
glycerol) as described [3,8,26]. The reaction mixtures were incubated
for 10 min on ice and resolved by electrophoresis on a 10% non-
denaturing PAG (40:1 acrylamide:bis-acrylamide) at 200 V, for 3 h
at 4‡C. Gels were dried and visualized by autoradiography. Quanti-
tations were obtained by optical densitometry of the ¢lms. Di¡erent
concentrations of TAR RNA (6, 12 and 20 nM) were titrated with
various concentrations of Tat R52 in the binding reactions. CD50
values were de¢ned as the Tat peptide concentration that displayed
50% binding to TAR RNA.
Binding inhibition by the monosaccharide derivatives was measured
by adding several concentrations of each compound to reaction mix-
tures containing 60 nM Tat R52 and 6 nM 32P-TAR, attaining 100%
binding of Tat-TAR in the absence of inhibitors [26]. The binding
inhibition values, CI50, were de¢ned as inhibitor concentrations that
displayed 50% inhibition of Tat-TAR binding.
Binding of aminoglycoside-arginine conjugates to TAR RNA was
measured by adding varying concentrations of each conjugate to re-
action mixtures (20 Wl) which contained 12 nM 32P-labelled TAR
RNA. The reactions were analyzed as described above. CD50 values
were de¢ned as the conjugate concentrations that displayed 50% bind-
ing to TAR RNA.
2.4. A⁄nity chromatography on L-arginine-Amberlite column
An L-arginine-Amberlite resin for a⁄nity chromatography was pre-
pared using the following procedure: ethanolamine was coupled to
the carboxyl groups of Amberlite IRC-50 using 1-(3-dimethylamino-
propyl) 3-ethylcarbodiimide, a water soluble coupler. The hydroxy
ethylene amide resin obtained was washed and dried and L-arginine
was coupled to the hydroxy groups using a standard cyanogen bro-
mide protocol. The ¢nal concentration of arginine residues was 12^16
WM/ml resin. The swollen L-arginine-Amberlite resin (200 Wl) was
packed into a plastic mini-column and equilibrated with bu¡er con-
taining 40 mM Tris-HCl, pH 7.5, 250 mM NaCl, 0.5 mM EDTA and
5 mM MgCl2 (bu¡er A). Approximately 1 ng of 32P-TAR RNA in
bu¡er A was loaded on the column. The column was eluted 3^5 times
with 400 Wl portions of bu¡er A, until no radioactivity was detected in
the eluent. The total radioactivity in the eluents did not exceed 3% of
the total radioactivity loaded. Each of the tested compounds was
dissolved in bu¡er A and passed through the column in 300 Wl por-
tions. Radioactivity of the eluates was determined by scintillation
counting on a LS 1701 Bruker counter. CE50 values, the concentra-
tions of inhibitors eluting 50% of the radioactive material from the
column, were determined. The eluate samples were proven to contain
TAR RNA by electrophoresis on a denaturing 12% polyacrylamide/7
M urea gel, followed by autoradiography.
The L-arginine-Amberlite a⁄nity resin, described above, was found
to be more mechanically stable and of better a⁄nity properties than
the L-arginine-agarose previously used (e.g. [8]). This may be due to
the higher arginine concentration and 6-atom spacer between the pol-
ymer and the arginine residues.
2.5. Cytotoxicity test
The cytotoxicity of the compounds was studied in LAN 1 (human
neuroblastoma), MPC11 (murine plasmacytoma) and MT4 (human
T-lymphocytes) cell cultures. Approximately 2.5U104 cells were
seeded per each well of the standard 96-well Falcon tissue cultural
plate in 200 Wl of DMEM containing 10% of heat-inactivated fetal calf
serum (FCS). Di¡erent concentrations of the compounds were added
to the wells in triplicates. After 24^48 h incubation, the cells were
washed and the medium was changed for the same amount of
DMEM/10% FCS containing 0.5 WCi of [3H]thymidine per well for
1 h. Then the medium was removed, the cells were washed with saline
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Fig. 1. The structures of 6-substituted MMP derivatives. Methyl 6-
deoxy-K-D-mannoheptopyranuronic acid amidoxime (6-amideoximo
MMP, 1) ; methyl 6-deoxy-K-D-mannoheptopyranuronic acid amide
(6-amido MMP, 2) ; methyl 6-deoxy-6-amino-K-D-mannopyranoside
(6-amino MMP, 3) ; methyl 6-deoxy-6-cyano-K-D-mannopyranoside
(6-cyano MMP, 4) ; methyl 6-deoxy-6-guanidino-K-D-mannopyrano-
side (6-guanidino MMP, 5) ; methyl 6-deoxy-6-(N-acetamidino)-K-D-
mannopyranoside (6-(N-acetamidino) MMP, 6) ; methyl 6-deoxy-6-
(N-L-arginineamido)-K-D-mannopyranoside (RMMP, 7). The synthe-
sis and characterization of these compounds are presented in [25].
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and the DNA was precipitated by ice-cold 10% trichloroacetic acid.
The precipitate was solubilized in 50 Wl 1 M NaOH, mixed with 4 ml
of Ultima Gold scintillation liquid (Packard) and counted on a LS
1701 Bruker scintillation counter.
2.6. Cellular uptake using £uorescent probes
The £uorescent derivative of the aminoglycoside-arginine conjugate
was prepared as described [27]. R4K was reacted with £uorescein
isothiocyanate (FITC, Sigma) in water-methanol-dimethyl sulfoxide
mixture for 24 h. FITC was added in 1:1 molar ratio which enabled
only one random amino group of the conjugate to react with FITC.
The £uorescein-labelled conjugate was puri¢ed by extraction with
acetone and absolute alcohol.
Hippocampal neurons from rat puppies were grown over rat glia
cells on polylysine-coated glass cover slides [28]. Human peripheral
blood mononuclear cells (PBMCs) were separated from a fresh blood
sample on a Ficoll gradient by the standard procedure. They were
cultured on polylysine-coated glass cover slides in RPMI medium,
containing 10% FCS, for 24 h. The cells were incubated in HEPES-
bu¡ered saline containing 0.1^1 mg/ml of R4K-£uorescein probe for
1.5^2 h. The slides were washed several times with saline and studied
by confocal laser-scanning microscopy on an Axiovert 100M (Zeiss)
microscope, using excitation at 488 nm (argon-ion laser) and emission
detected in a band of 505^550 nm [28].
3. Results
3.1. Monosaccharide derivatives
We prepared a set of 6-substituted derivatives of methyl K-
D-mannopyranoside (MMP) (Fig. 1) in order to determine
which side chain attached to a monosaccharide moiety would
display the highest a⁄nity to TAR RNA. These compounds
were tested for their a⁄nity to TAR on an L-arginine-Amber-
lite column, and their potential inhibition of Tat-binding to
TAR, using the gel-shift assay. We observed that 6-guanidino
6-deoxy MMP (5) and 6-(N-acetamidino) 6-deoxy MMP (6)
(Fig. 1) eluted 32P-labelled TAR RNA from the column with
CE50 of 650 mM and 730 mM, respectively, which is signi¢-
cantly lower than the CE50 of arginine (1500 mM). All the
other tested monosaccharide derivatives displayed CE50 values
of approximately 1500 mM or higher (Table 1). The gel-shift
assays demonstrated that 6-guanidino MMP (5) and 6-(N-
acetamidino) MMP (6) inhibited the binding of 60 nM Tat
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Fig. 2. The structures of kanamycin and gentamicin C conjugates with arginine. R4K is the major product (V90% in the mixture), the tetra-
substituted derivative of the kanamycin A isomer. R3G is a mixture of tri-substituted derivatives of gentamicin C1 and C2 isomers. R4GC1a is
a tetra-substituted derivative of the puri¢ed gentamicin C1a isomer.
Table 1
Concentrations of the compounds that eluted 50% of TAR RNA
(CE50) from the arginine-Amberlite a⁄nity column
Compound CE50 (mM)
R52 Tat peptide 0.5
Arginine HCl 1500
6-Amidoximo MMP (1) s 1500
6-Amido MMP (2) s 1500
6-Amino MMP (3) s 1500
6-Cyano MMP (4) 1200
6-Guanidino MMP (5) 650
6-(N-Acetamidino) MMP (6) 730
RMMP (7) 310
R4K 2.5
R3G mixture 1.4
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R52 peptide to 6 nM TAR RNA with CI50 values of 9 and 11
mM, respectively. These CI50 values were normalized to the
conditions presented by Frankel et al. [8], giving apparent Ki
values of around 1 mM, suggesting that the 6-guanidino
MMP (5) and 6-(N-acetamidino) MMP (6) are stronger inhib-
itors of Tat-TAR binding than the free arginine, and are
similar to L-argininamide, agmatine [8], and neomycin B
[23]. All other monosaccharide derivatives did not show sig-
ni¢cant inhibition of Tat binding to TAR (Table 2). These
results indicate that a compound comprised of a carbohydrate
‘core’ attached to a single strongly basic group with the ge-
ometry resembling that of guanidine, may serve as a speci¢c
inhibitor of Tat binding to TAR.
The arginine-MMP conjugate (RMMP (7)) was prepared
[25] and its a⁄nity to TAR was determined as described
above. We found that 310 mM of RMMP eluted 50% of
the TAR RNA from the a⁄nity column (Table 1). The gel-
shift assay revealed that RMMP inhibited the Tat-TAR inter-
action with a CI50 of 1.8 mM which corresponds to an appa-
rent Ki of approximately 160 WM (normalized as above [8])
(Fig. 3A and Table 2). Having compared the CI50 (or Ki)
values of RMMP to the corresponding values of 6-guanidino
MMP (5) and 6-(N-acetamidino) MMP (6), we concluded that
not only a carbohydrate core facilitates the binding of the
inhibitor, which contains a guanidinium (and acetamidinium)
group, to TAR RNA, but a longer chain, connecting the core
and the charge-bearing moiety, is also bene¢cial. Hence the
‘best building block’ for a potent antiviral peptidomimetic
compound was considered to be a monosaccharide-arginine
conjugate.
3.2. Aminoglycoside-arginine conjugates
In order to obtain oligomeric derivatives, we modi¢ed com-
mercial aminoglycoside antibiotics, kanamycin and gentami-
cin C by attaching arginine moieties through amide bonds
using standard peptide chemistry methods. In particular, con-
jugates of L-arginine with kanamycin, gentamicin C and gen-
tamicin C1a were synthesized (Fig. 2 and [25]).
Kanamycin (Fluka) is a mixture of the three major com-
pounds, kanamycins A, B and C, of which the A isomer was
the most abundant (V80%). As expected, a kanamycin A
derivative comprised approximately 90% of the arginine-ka-
namycin conjugate (R4K) mixture. 1H and 13C NMR spectros-
copy, as well as 2D NMR studies, con¢rmed the purity and
chemical structure of the conjugate which was found to have a
4:1 arginine to antibiotic ratio (Fig. 2). A mass peak of 1109.7
Da (calculated 1109.25 Da) was observed in FAB mass spec-
trum [25].
Gentamicin C (Nova-Biochem) is a mixture of three com-
ponents, C1, C2 and C1a, that di¡er by methylation of a
single amino group and adjacent CH2 (Fig. 2) [29]. The com-
ponents were separated chromatographically, as previously
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Fig. 3. Electrophoretic mobility shifts. A: Inhibition of Tat R52 peptide binding to TAR RNA by RMMP (7) (60 nM of Tat R52, 6 nM
TAR). B: Binding of R4K to TAR RNA (12 nM). Supposed a 2:1 ratio of R4K to TAR RNA in the complex. C: Binding of the R3G mix-
ture to TAR RNA (12 nM). Complexes of increasing molecular weight are observed and the RNA precipitation in wells is shown (the empty
gel space between the horizontal lines is deleted). D: R4GC1a binding to TAR RNA (20 nM). Supposed a 1:1 ratio of R4GC1a to TAR
RNA in the complex. The concentration of Tat R52 in the control lanes is 200 nM.
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described [29]. The ratio of the isomers was 4:3:1 [25]. The
arginine-gentamicin conjugate mixture (R3G) contained
mainly species of three arginine residues attached to the anti-
biotic core (Fig. 2), as was con¢rmed by 1H and 13C NMR.
FAB MS revealed two prominent mass peaks of 948.3 and
934.3 Da (calculated 948.1 and 934.1 Da), which correspond
to tri-arginine derivatives of the C1 and C2 isomers, the major
components of the mixture. The R4GC1a conjugate of argi-
nine with pure C1a gentamicin isomer was also prepared. This
conjugate comprised essentially one product, which contained
four arginine residues (Fig. 2), according to 1H and 13C NMR
[25].
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Table 2
Concentrations of the compounds that displayed a 50% inhibition (CI50) and a 50% binding (CD50) in gel-shift experiments on TAR RNA
Compound CI50 (mM) CD50 (mM) TAR RNA (nM)
Tat R52 peptide 6^12a 2a
Tat R52 peptide 35 6
Tat R52 peptide 75 12
Tat R52 peptide 200 20
Arginine HCl 4b 2b
Arginine HCl 38 6
6-Amidoximo MMP (1) s 50 6
6-Amido MMP (2) s 50 6
6-Amino MMP (3) 56 6
6-Cyano MMP (4) 46 6
6-Guanidino MMP (5) 9 6
6-(N-Acetamidino) MMP (6) 11 6
RMMP (7) 1.8 6
R4K 2500 12
R3G mixture 500 12
R4GC1a 200 20
aReference [3].
bReference [8].
Fig. 4. Confocal microscopy images of live cells stained with R4K-FITC. Images were taken with the 63U water immersion objective. A: Rat
hippocampal neurons incubated with 1 mg/ml R4K-FITC for 2 h. B: The same two cells at a higher magni¢cation and contrast: an intense £u-
orescence is observed in the nuclei. C: Optical microscopy of human PBMCs. D: The same ¢eld, confocal microscopy at 488 nm excitation.
The £uorescence is observed. E: Superposition of images C and D. Fluorescence is localized in the nuclei.
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3.3. Binding of aminoglycoside-arginine conjugates to TAR
RNA
The ability of aminoglycoside-arginine conjugates to bind
TAR RNA was studied using the L-arginine-Amberlite a⁄nity
column. We found that the concentrations of R4K and R3G
conjugates needed to elute 50% of the labelled TAR from the
column (CE50 values of 2.5 mM and 1.4 mM, respectively,
Table 1) were comparable to that obtained for Tat R52 pep-
tide (CE50 value of 0.5 mM, Table 1). This result suggests that
the aminoglycoside-arginine conjugates bind to the RNA with
similar e⁄ciency as Tat peptide and compete for the same
arginine-binding site on TAR.
The molecular weights of the aminoglycoside-arginine con-
jugates (about 940, 1076 and 1109 Da for R3G, R4GC1a and
R4K, respectively) are close to that of the Tat R52 peptide
(1434 Da), thus their binding to TAR RNA was clearly ob-
served as electrophoretic band shifts (Fig. 3). All the conju-
gates displayed a high a⁄nity to TAR RNA, the binding of
R4K to 12 nM 32P-labelled TAR was observed with a CD50 of
2.5 WM (Fig. 3B, Table 2). The band shifts observed for the
R4K complex with TAR remained unchanged at increasing
concentrations of R4K in the range of 1^5 WM. Since a Tat-
TAR complex has a 1:1 stoichiometry and the band shift of
the R4K-TAR complex was observed to be approximately
twice that of Tat R52-TAR (Fig. 3B), we suggested a 2:1 ratio
of the R4K conjugate to RNA in the complex. The R3G
conjugate displayed binding to 12 nM of TAR with a CD50
of about 500 nM (Fig. 3C, Table 2). The gel mobility of R3G-
TAR complexes declined signi¢cantly with the increase of
R3G concentration in the range of 0.5^4 WM, as was observed
from the increase of the band shifts and an increasing precip-
itation of the complexes in the wells was observed (Fig. 3C).
At the same concentration of TAR (12 WM), the CD50 of Tat
R52 was found to be 75 nM (Table 2). The R4GC1a conju-
gate formed a complex with 20 nM of TAR RNA at concen-
trations starting from 200 nM. The CD50 of Tat R52 at the
same concentration of TAR RNA was 200 nM. By comparing
the gel shift of R4GC1a-TAR to that of Tat R52-TAR, we
suggested that the ratio of R4GC1a to the RNA in the com-
plex is 1:1 (Fig. 3D, Table 2). An approximate linear depend-
ence of Tat R52 CD50 values on TAR RNA concentrations
was observed (Table 2). We have normalized the CD50 values,
obtained in our study, to the reported conditions [3], and
apparent Kd values, suitable for comparison with the reported
data, were produced. The apparent Kd values for the conju-
gate complexes with TAR RNA were found to be 416 nM for
R4K, 83 nM for R3G and approximately 20 nM for R4C1a
(within less than 20% estimated error). Thus, a tri-saccharide
core bearing three or four arginine residues can successfully
mimic the binding pattern of Tat.
3.4. Cytotoxicity test
All the compounds were tested for their toxicity in at least
two of the three above mentioned cell culture lines. We found
that none of the compounds up to a concentration of 1 mM
caused any cell growth inhibition, as it was measured by
[3H]thymidine incorporation.
3.5. Cellular uptake using £uorescent probes
Uptake of the conjugate compounds by cells and intracel-
lular distribution was studied using a £uorescent derivative of
R4K (R4K-FITC).
After incubation of live rat hippocampal neurons with 1
mg/ml R4K-FITC for 2 h, an intense £uorescence was ob-
served in the cells, indicating an e⁄cient uptake of the probe
(Fig. 4A). Even higher £uorescence was detected in the cell
nuclei, suggesting that the R4K-£uorescein is associated with
nucleic acids, as was expected (Fig. 4B). Live human PBMCs
were treated with 0.1 mg/ml of R4K-FITC for 1.5 h. The
accumulation of the £uorescent probe was observed in the
cell nuclei (Fig. 4C,D,E).
4. Discussion
The conjugates of aminoglycoside antibiotics with arginine
comprise a completely new class of peptidomimetic substan-
ces. The aminoglycoside-arginine conjugates resemble oligoca-
tionic peptides by their chemical properties, but it is not likely
that they would be recognized by intracellular proteolytic en-
zymes. Conjugate structures share features of relative rigidity
of the pyranoside sugar rings, with relative £exibility of inter-
ring and side chain links. It is clear that guanidinium groups
are important for the ligand-TAR interaction. General fea-
tures of the ligand molecule which provide groove binding
also play a signi¢cant role in HIV and BIV Tat protein com-
plexation with their respective TAR elements [10^12], as well
as in the HIV Rev interaction with the RRE responsive struc-
ture [30]. Aminoglycoside antibiotics are known to bind in the
RNA major groove: e.g. tobramycin binds in the stem-loop
junction of the RNA aptamer [31] and parmomycin and neo-
mycin bind in the A-site of 16S RNA [32,33]. We suggest that
the aminoglycoside-arginine conjugates, presented in this
study, can bind in the TAR RNA major groove. Arginine
side chains probably interact with nucleotides in the bulge
region, while the glycoside core provides additional ligand-
RNA contacts near the TAR loop.
Based on our study, we can propose some structural fea-
tures of aminoglycoside derivative binding to TAR. As we
observed, a sugar ring facilitates binding of the compound
to the RNA, especially when the ring and the guanidinium
groups are separated by a spacer of suitable length. Thus, 6-
guanidino MMP (5) displayed six-fold lower activity then
RMMP (7). It is likely that the guanidinium group can be
substituted for the acetamidinium one, since the Ki values of
6-guanidino MMP (5) and 6-(N-acetamidino) MMP (6) are
similar. It is worth noting that streptomycin, bearing two
guanidino groups on the deoxystreptamine ring is not an e⁄-
cient inhibitor of the peptide-RNA interaction [23]. So far L-
arginine seems to be the best ‘building block’, but it is not
necessarily the only one. Conjugates, bearing side chains of
varied lengths with terminal guanidine or acetamidine groups,
may also prove to be potent TAR RNA binders. Such con-
jugates can be prepared e.g. by modi¢cation of the terminal
amino group of lysines or L-alanines (four or two methylene
groups in the side chain respectively).
Arginine-saccharide oligomers bind TAR RNA signi¢cantly
stronger than monomers. It is enough to recruit only four
arginine residues to reach nanomolar Kd values. It is worth
noting that the conjugate containing three arginine residues
per molecule (R3G) binds RNA ¢ve-fold more e⁄ciently than
the conjugate with four arginine residues per molecule (R4K).
This observation suggests that the geometry of the conjugate
is ultimately more important than the number of arginine side
chains. Since all the gentamicin derivatives contain an un-
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modi¢ed amino sugar ring (Fig. 2), it is plausible that such a
ring favors groove binding near the TAR RNA loop, similar
to tobramycin ring III [31]. The R4GC1a conjugate, which
contains an unmodi¢ed amino sugar ring and four arginine
residues, binds to TAR RNA almost as e⁄ciently as the Tat
R52 peptide does. The conjugates form di¡erent complexes
with the RNA, as was observed from their band shifts. We
assume that R4K and R4GC1a conjugates form soluble com-
plexes with the RNA at 2:1 and 1:1 ligand to RNA ratio,
respectively. The R3G conjugate mixture forms complexes of
varying stoichiometry, and precipitates the RNA at relatively
low concentrations, probably due to the formation of
branched agglomerates. Structure-functional relationship of
the conjugate-TAR RNA interactions will be further investi-
gated by footprinting analysis, NMR structural studies and by
X-ray crystallography.
Fluorescent labelling studies indicate that the conjugates are
subject to intracellular transport. Preferentially intranuclear
accumulation suggests their general a⁄nity to nucleic acids.
In conclusion, the aminoglycoside-arginine conjugates,
R4K, R3G and R4GC1a, displayed a high a⁄nity to the
target TAR RNA and were found to be non-toxic for cultured
cells even at relatively high concentrations. The synthesis of
the conjugates utilizes naturally occurring antibiotics and re-
quires fewer steps than peptide or peptoid preparation. There
is strong evidence that the conjugates penetrate into live cells.
All these features make aminoglycoside-arginine conjugates
attractive candidates for antiretroviral drug design.
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